Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
about
Can active components of licorice, glycyrrhizin and glycyrrhetinic acid, lick rheumatoid arthritis?Nonsteroidal Anti-inflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational StudiesEnhanced NF-κB activity impairs vascular function through PARP-1-, SP-1-, and COX-2-dependent mechanisms in type 2 diabetes.Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicityNon-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.The leukotriene receptor antagonist montelukast and aortic stenosisMolecular interaction study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 kinase and JNK kinase.The Effect of Gabapentin Plus Celecoxib on Pain and Associated Complications After Laminectomy.Inflammatory mediators in saliva associated with arterial stiffness and subclinical atherosclerosis.Non-steroidal anti-inflammatory drugs and the risk of atrial fibrillation: a population-based follow-up study.Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer.Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review.Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes.Celecoxib for the treatment of atherosclerosis.Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.The effect of some 4,2 and 5,2 bisthiazole derivatives on nitro-oxidative stress and phagocytosis in acute experimental inflammation.COX Inhibition Profile and Molecular Docking Studies of Some 2-(Trimethoxyphenyl)-Thiazoles.Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.
P2860
Q26779680-BAA95ED4-53E4-4A86-A4AD-8DEAD16F24AFQ28079436-592C4519-E686-4141-85AE-FBF77AD2EC3EQ30540016-47CF782F-F343-491F-9BCC-3FA16D542BAEQ33959603-698D2DCA-C6F0-46B9-8CE6-B94BF6C6B7BAQ36233306-62DC4CEA-FDFA-47D8-9C6C-A715FA7A3FFEQ36562551-E6E7C1C1-8CF7-46C3-8332-89D428DF0EF6Q36727886-97BB39F4-A18A-405B-8FA6-7886FCEDAC95Q36831286-A0663A66-9D4E-4CA9-851A-B5BF5465E5EFQ37284714-34FDA3B2-BCAE-4C16-A725-F9660C70174BQ37704435-6DA655F4-4051-49D8-A187-2FC44470DF73Q38027501-3A9C43D6-F42D-403E-BB89-864AA94E5FC6Q38068081-3B9B248D-442B-4B49-B547-D91F5B56A882Q38249105-DD799BEC-35BE-4DF5-AD98-B622AB7C2AA4Q38759585-677EA8B0-CB42-4277-990C-7FEDC8843BB2Q38777815-56569642-DE2B-4E77-9671-217708302213Q46870956-D80BF35C-03DF-40EA-B2C8-7FA37F115122Q48004224-69DB6A7A-8335-4B48-83B5-AA5CCD415E7FQ52853892-BEA1786E-A963-4478-9712-64BBD8DB43AB
P2860
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Cyclooxygenase-2 inhibitors an ...... r the withdrawal of rofecoxib.
@en
Cyclooxygenase-2 inhibitors an ...... r the withdrawal of rofecoxib.
@nl
type
label
Cyclooxygenase-2 inhibitors an ...... r the withdrawal of rofecoxib.
@en
Cyclooxygenase-2 inhibitors an ...... r the withdrawal of rofecoxib.
@nl
prefLabel
Cyclooxygenase-2 inhibitors an ...... r the withdrawal of rofecoxib.
@en
Cyclooxygenase-2 inhibitors an ...... r the withdrawal of rofecoxib.
@nl
P2860
P356
P1476
Cyclooxygenase-2 inhibitors an ...... r the withdrawal of rofecoxib.
@en
P2093
P2860
P304
P356
10.1093/EURHEARTJ/EHR421
P577
2011-11-21T00:00:00Z